Cartography Biosciences and Samsung Ventures today announced a strategic investment to support the advancement of Cartography’s differentiated oncology pipel...

Cartography Biosciences secures strategic investment from Samsung Ventures for oncology pipeline. May 7, 2026 South San Francisco-based Cartography Biosciences has received a strategic equity investment from Samsung Ventures to support the advancement of its oncology pipeline and proprietary antigen discovery platforms. The investment amount was not disclosed. The capital was deployed through the Samsung Life Science Fund, which was established by Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C\&T, and is managed by Samsung Ventures. The fund directs capital toward biopharmaceutical companies working across biologics, gene editing, and AI-enabled therapeutics. No additional participating investors were named. Cartography said the partnership is intended to leverage Samsung's life sciences network alongside the company's own antigen discovery and drug development capabilities. The Samsung investment follows a USD 67 million Series B closed in October 2025, led by Pfizer Ventures, with participation from LG Corp, Amgen Ventures, Finchley Healthcare Ventures, Global BioAccess Fund, and Lotte Holdings CVC. The company's first financing - a combined seed and Series A totaling USD 57 million - was raised in July 2022 and led by 8VC. Cartography's pipeline centers on antibody-based therapies designed to engage the immune system against solid tumors. Its lead candidate, CBI-1214, is a T-cell engager targeting LY6G6D in microsatellite stable and microsatellite instability-low colorectal cancer - a patient population with limited options under current immunotherapy approaches. CBI-1214 entered the clinic in early 2026 and is currently enrolling patients in a Phase I study. The company's broader pipeline, while not fully disclosed in public materials, is built around the same antigen discovery logic and is focused on oncology indications where tumor selectivity represents a clinical differentiator. The platforms underpinning Cartography's pipeline - ATLAS and SUMMIT - are designed to address a persistent challenge in cancer immunotherapy: on-target, off-tumor toxicity arising from the expression of therapeutic targets on healthy tissue. ATLAS generates single-cell resolution maps of antigen expression across both normal human tissues and patient tumors, drawing on a dataset the company describes as spanning hundreds of thousands of cell states. The scientific rationale for this approach is that bulk sequencing methods average gene expression across mixed cell populations and can obscure rare but clinically relevant expression in normal tissues - a resolution gap that single-cell profiling is designed to close. The SUMMIT platform extends this logic by identifying combinations of antigens whose co-expression is restricted to tumor cells, even when individual antigens within the combination are also found on healthy tissue. This AND-gate combinatorial strategy is intended to expand the pool of actionable targets beyond what single-antigen approaches allow. In January 2026, Cartography announced a collaboration with Pfizer under which it will apply ATLAS and SUMMIT to identify tumor-selective antigens in an undisclosed indication. The deal includes up to USD 65 million in upfront and near-term milestone payments, with total potential value reaching USD 865 million. Pfizer Ventures had joined the Series B just months prior, with Michael Baran, Partner at Pfizer Ventures, joining Cartography's board as part of that round. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/